Figure 5
From: Topical netarsudil for the treatment of primary corneal endothelial degeneration in dogs
Clinical improvement or stabilization of clinical disease did not significantly differ for canine patients receiving topical netarsudil versus those receiving vehicle. There was no significant correlation between the proportion of eyes that were improved or remained stable on patients in the netarsudil group that received netarsudil for 4 months when compared with eyes in the vehicle control group at 4 months (A, P = 0.77 Fisher exact test, Freeman-Halton extension). Similarly, there was no significant difference in progression in the vehicle control group during the first 4 months of vehicle treatment versus the last 4 months with netarsudil treatment (B, P = 0.35, Fisher exact test, Freeman-Halton extension).
